Summary

The German insulin delivery device market is an important subset of the greater medical device landscape, distinguished by ongoing innovation and a focus on improving patient experience and treatment efficacy. The rising prevalence of diabetes, technical developments in insulin delivery systems, more awareness about diabetes management, and favourable government measures supporting healthcare infrastructure are all driving growth in this market. Germany, as one of Europe's largest healthcare markets, has a strong infrastructure and high healthcare spending, which encourages the expansion of the insulin delivery device business. The insulin delivery system market is diverse, covering insulin pumps, insulin syringes, insulin pens, and insulin jet injectors. Insulin pens, in particular, have seen widespread use because of their simplicity, ease of use, and accurate dosing capabilities. Continuous innovation in insulin delivery technology is still a major market driver in Germany. Manufacturers are constantly striving to produce new devices with features such as Bluetooth connectivity, smartphone integration, and increased dosing precision. Furthermore, the emphasis on creating smart insulin pens and pumps with integrated continuous glucose monitoring (CGM) capabilities is influencing the future diabetes management landscape in Germany. Furthermore, the growing preference for less invasive and needle-free insulin delivery methods has spurred the country's research and development activities. Needle-free devices, such as jet injectors, are gaining popularity due to their painless delivery and lower risk of needle-associated problems, making them particularly appealing to paediatric and needle-averse patients. Partnerships, collaborations, and strategic alliances between pharmaceutical companies, device makers, and healthcare providers have increased in recent years, promoting innovation and market expansion. These collaborations attempt to provide integrated diabetes management solutions that combine medications, devices, and digital technology.

According to the research report "Germany Insulin Delivery Devices Market Overview, 2028," published by Bonafide Research, the Germany Insulin Delivery Devices market is expected to reach market size of more than USD 1 Billion by 2028. According to the German Diabetes Centre (DDZ) 2022, diabetes affects more than 8 million individuals in Germany. Over the next two decades, the number of people with type 2 diabetes in Germany will rise. According to DDZ researchers, more than 12 million people might be suffering from metabolic problems by 2040. Germany is a developed country with superior healthcare services. Continuous glucose monitoring and insulin infusion pumps are being implemented more quickly in Germany than in other emerging countries. Furthermore, reimbursement and price rules are strictly regulated, which speeds up the adoption of new and advanced technology. Medical devices, particularly insulin delivery devices, are subject to high regulatory regulations in Germany. Regulatory bodies in the country, such as the Federal Institute for Drugs and Medical Devices (BfArM), ensure the safety and efficacy of these devices, encouraging trust among both healthcare professionals and patients. The reputation of Germany for technological innovation extends to the healthcare sector. German firms are well-known for creating cutting-edge insulin administration equipment like pumps, pens, and continuous glucose monitoring systems. Digital health technologies are gradually being integrated into Germany's healthcare system. Insulin delivery devices are becoming more connected, enabling data sharing with healthcare practitioners. This connectivity allows for remote monitoring and personalised care, which improves treatment efficacy. The German market has a wide range of preferences for insulin administration systems. While insulin pumps are commonly used, insulin pens are still widely used due to their convenience and ease of use. This varied adoption reflects the country's proclivity to accommodate a wide range of patient demands and preferences.

Based on product market is segmented into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices(insulin transdermal patches, insulin inhalers, insulin jet injection). Among them market is majorly dominated by insulin pens product with significant market share. In comparison to alternative delivery techniques such as syringes or pumps, insulin pens provide unsurpassed convenience and ease of use. Their simple design and pre-filled cartridges make them easy to use, especially for people who manage diabetes on a daily basis. This simplicity appeals to a broad spectrum of patients, including the elderly and those with limited dexterity. In Germany, insulin pens have received universal acceptability among patients and healthcare providers. They have become a recognised and trusted insulin administration mechanism throughout the years, contributing to their dominant market position. Insulin pens are widely used in healthcare facilities and hospitals, which influences patient’s familiarity with and acceptability of this form of administration. Patients who use insulin pens while in the hospital generally choose to continue using them at home. In terms of end user market includes home care, hospitals and clinics and others. Insulin delivery devices are widely used in home care settings and is major end user segment in Germany insulin delivery devices market. The use of insulin administration systems like pens and pumps at home provides unrivalled convenience. Insulin delivery can be easily incorporated into patient’s everyday activities without causing disruption, supporting better adherence to treatment regimens. Insulin delivery systems reduce the need for frequent hospital trips only for insulin administration. This lessens the strain on healthcare institutions while allowing patients to concentrate on their regular activities without interruption. The use of insulin delivery devices at home enhances continuity of care. Patients receive consistent care with no interruptions, resulting in better disease management and health outcomes.

Based on indication market is divided into diabetes, pregnancy, cardiovascular disorders & hypertension, respiratory diseases, hearing disorders, cancer, movement disorders, wound care and other indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV). Among them insulin delivery devices majorly found indication in diabetes patients and is expected to lead the market of Germany with significant market share. Diabetes is a common chronic disease in Germany, with a large proportion of the population requiring insulin therapy to control blood glucose levels. As of the large number of diabetic patients, insulin delivery systems must be widely used. Insulin therapy is a fundamental and necessary treatment strategy for many people with diabetes, particularly those with type 1 diabetes and some with type 2 diabetes. Insulin delivery systems meet a critical need in diabetes management by providing a convenient and effective way to inject insulin. The trend towards personalised medicine has resulted in diabetes patients receiving specific treatment strategies. Insulin delivery systems provide dosage and regimen customization flexibility, which aligns with the growing need for personalised healthcare solutions.

Considered in this report:
• Geography: Germany
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Germany Insulin Delivery Devices market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product:
• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices(Insulin transdermal patches, Insulin inhalers, Insulin jet injection)

By End User:
• Home Care
• Hospitals & Clinics
• Others

By Indication:
• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Insulin Delivery Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

ページTOPに戻る

Table of Contents